Free Trial

1,415 Shares in STERIS plc (NYSE:STE) Purchased by T. Rowe Price Investment Management Inc.

STERIS logo with Medical background

T. Rowe Price Investment Management Inc. bought a new stake in shares of STERIS plc (NYSE:STE - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,415 shares of the medical equipment provider's stock, valued at approximately $291,000.

Several other hedge funds have also added to or reduced their stakes in the business. Franklin Resources Inc. increased its position in shares of STERIS by 171.2% in the third quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider's stock valued at $191,370,000 after acquiring an additional 529,308 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in STERIS by 30.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,970 shares of the medical equipment provider's stock worth $2,275,000 after buying an additional 2,583 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in STERIS in the third quarter worth about $9,949,000. Merit Financial Group LLC purchased a new position in shares of STERIS during the 4th quarter worth approximately $260,000. Finally, Blue Trust Inc. lifted its stake in shares of STERIS by 19.9% in the 4th quarter. Blue Trust Inc. now owns 1,128 shares of the medical equipment provider's stock valued at $232,000 after purchasing an additional 187 shares during the period. 94.69% of the stock is owned by institutional investors.

STERIS Stock Performance

Shares of STE traded up $2.47 on Friday, reaching $224.71. The company's stock had a trading volume of 745,458 shares, compared to its average volume of 537,685. The stock's 50 day simple moving average is $223.09 and its two-hundred day simple moving average is $218.87. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.13 and a quick ratio of 1.40. The stock has a market capitalization of $22.08 billion, a P/E ratio of 47.71 and a beta of 0.87. STERIS plc has a 12-month low of $200.98 and a 12-month high of $248.24.

STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. Research analysts forecast that STERIS plc will post 9.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on STE. Stephens reiterated an "overweight" rating and issued a $240.00 price target on shares of STERIS in a research note on Thursday, February 6th. Piper Sandler lifted their price target on STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. JMP Securities reissued a "market outperform" rating and set a $265.00 price objective on shares of STERIS in a research report on Thursday, April 10th. Finally, Needham & Company LLC restated a "hold" rating on shares of STERIS in a research note on Monday, April 7th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $258.75.

Check Out Our Latest Report on STE

STERIS Company Profile

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

See Also

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Should You Invest $1,000 in STERIS Right Now?

Before you consider STERIS, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.

While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in May 2025
3 Stocks Offering Rare Generational Buying Opportunities
Make Your Money Work Harder: The Power of Dividend Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines